Trials / Terminated
TerminatedNCT05905783
Hidradenitis Suppurativa Study of Izokibep
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- ACELYRIN Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Solution for injection |
| DRUG | Izokibep | Solution for injection |
Timeline
- Start date
- 2023-06-22
- Primary completion
- 2024-07-24
- Completion
- 2025-01-27
- First posted
- 2023-06-15
- Last updated
- 2025-10-15
- Results posted
- 2025-10-15
Locations
98 sites across 8 countries: United States, Canada, France, Germany, Hungary, Japan, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05905783. Inclusion in this directory is not an endorsement.